-
(3E)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione
-
ChemBase ID:
436
-
Molecular Formular:
C15H13N3O4S
-
Molecular Mass:
331.34642
-
Monoisotopic Mass:
331.06267691
-
SMILES and InChIs
SMILES:
S1(=O)(=O)N(/C(=C(/O)\Nc2ncccc2)/C(=O)c2c1cccc2)C
Canonical SMILES:
O/C(=C/1\C(=O)c2ccccc2S(=O)(=O)N1C)/Nc1ccccn1
InChI:
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,20H,1H3,(H,16,17)/b15-13+
InChIKey:
LDJVNWFKNMYYNT-FYWRMAATSA-N
-
Cite this record
CBID:436 http://www.chembase.cn/molecule-436.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
(3E)-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-3,4-dihydro-2H-1$l^{6},2-benzothiazine-1,1,4-trione
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Apo-Piroxicam
|
Artroxicam
|
Baxo
|
Bruxicam
|
Caliment
|
Erazon
|
Feldene
|
Flogobene
|
Geldene
|
Improntal
|
Larapam
|
Pipoxicam
|
Pirkam
|
Piroflex
|
Reudene
|
Riacen
|
Roxicam
|
Roxiden
|
Sasulen
|
Solocalm
|
Zunden
|
piroxicam usp
|
Akten
|
|
|
Synonyms
|
piroxicam
|
AK1015
|
Piroxicam
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
7.5554237
|
H Acceptors
|
6
|
H Donor
|
2
|
LogD (pH = 5.5)
|
1.230431
|
LogD (pH = 7.4)
|
1.0765729
|
Log P
|
1.3089457
|
Molar Refractivity
|
96.1692 cm3
|
Polarizability
|
32.561253 Å3
|
Polar Surface Area
|
99.6 Å2
|
Rotatable Bonds
|
2
|
Lipinski's Rule of Five
|
true
|
Log P
|
1.81
|
LOG S
|
-3.74
|
Solubility (Water)
|
6.05e-02 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Solubility
|
23 mg/L
|
Show
data source
|
|
Hydrophobicity(logP)
|
3
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB00554
|
Item |
Information |
Drug Groups
|
approved; investigational |
Description
|
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem] |
Indication |
For treatment of osteoarthritis and rheumatoid arthritis. |
Pharmacology |
Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. |
Toxicity |
Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting. |
Affected Organisms |
• |
Humans and other mammals |
|
Biotransformation |
Renal |
Absorption |
Well absorbed following oral administration. |
Half Life |
30 to 86 hours |
Elimination |
Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk. |
Distribution |
* 0.14 L/kg |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent